Drug Trial Radar · NCT02112214
Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population
Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5,224
Planned (sponsor's estimate)
Start
Jun 2014
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- National Cancer Center, KoreaGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- International Agency for Research on Cancer; Chonnam National University Hospital; Chung-Ang University Hospital; Pusan National University Hospital; Kyungpook National University Hospital; Uijeongbu St. Mary's Hospital/The Catholic University; Kangdong Sacred Heart Hospital; Incheon St.Mary's Hospital/The Catholic University; SMG-SNU Boramae Medical Center; Chuncheon Sacred Heart Hospital; Kosin University Gospel Hospital
- First posted
- Apr 11, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 40 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to define the role of H. pylori eradication in the prevention of gastric cancer and its precursors in the context of a population-based endoscopic screening program.
Conditions
- Gastric Cancer
- Helicobacter Pylori Infection
Interventions
10-day bismuth-based quadruple therapyDrug
Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days
PlaceboOther
Placebo for bismuth-based quadruple therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of gastric cancer between the intervention and placebo groupsTime frame: Up to 10 years After H. pylori eradication
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Kosin University Gospel Hospital
Busan, South Korea
Pusan National University Hospital
Busan, South Korea
Hallym University Chuncheon Sacred Heart Hospital
Chuncheon, South Korea
Kyungpook National University Hospital
Daegu, South Korea
National Cancer Center
Goyang, South Korea
Chonnam National University Hospital
Gwangju, South Korea
Incheon St.Mary's Hospital/The Catholic University
Incheon, South Korea
Kandong Sacred Heart Hospital
Seoul, South Korea
SMG-SNU Boramae Medical Center
Seoul, South Korea
Chung-Ang University Hospital
Seoul, South Korea
Uijeongbu St. Mary's Hospital/The Catholic University
Uijeongbu-si, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.